Nasus Pharma Ltd. announced a collaboration with Aptar to support the development and commercialization of NS002, an intranasal powder epinephrine product. This collaboration will help accelerate NS002’s path to market and reduce development risks by providing access to Aptar’s Unit Dose System technology. Nasus Pharma is focused on developing intranasal powder products for acute medical conditions, with NS002 being developed as a needle-free alternative to epinephrine autoinjectors for anaphylaxis patients. The collaboration includes regulatory support with the FDA and EMA, leveraging Aptar’s technical expertise and manufacturing capabilities.

For more information about Nasus Pharma, visit their website at www.nasuspharma.com or follow them on Twitter and Linkedin. This collaboration with Aptar is a significant milestone for Nasus Pharma and the NS002 program, providing a validated dosing infrastructure and established regulatory pathways for commercialization. Forward-looking statements in the press release highlight the potential market opportunity for NS002 and the benefits of the collaboration in accelerating the product’s path to market. Nasus Pharma is committed to advancing NS002 through current clinical development to commercialization in alignment with their timeline and objectives.

Read more at GlobeNewswire: Nasus Pharma Announces Expanded Agreement to Support